Early Outcomes of Arthroscopic Versus Open Reduction for Developmental Dysplasia of the Hip in Ch… (NCT06747767) | Clinical Trial Compass
CompletedNot Applicable
Early Outcomes of Arthroscopic Versus Open Reduction for Developmental Dysplasia of the Hip in Children
Iraq43 participantsStarted 2022-01-15
Plain-language summary
This study was designed to determine whether arthroscopic-assisted reduction offers better early surgical outcomes than open reduction for treating developmental dysplasia of the hip in children. By comparing these two approaches, the researchers sought to find out if using an arthroscopic-assisted method could lower redislocation rates, shorten operative time, reduce blood loss, maintain acceptable acetabular alignment, and potentially decrease the risk of complications such as avascular necrosis, thereby improving the quality of care and long-term hip function for affected children.
Who can participate
Age range
1 Year – 2 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Children diagnosed with DDH (Tönnis grade II-IV)
* Age range: 12 to 24 months at the time of the first surgical reduction
* A documented failed attempt at conservative reduction (e.g., closed reduction) prior to enrollment
Exclusion Criteria:
* Presence of neuromuscular disorders
* Teratologic hip dislocation
* Prior surgical intervention on the affected hip
* Incomplete radiographic documentation (missing radiographs at any of the required assessment intervals)
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
rate of hip redislocation documented clinically and radiographically at 6, 12, and 24 months postoperatively.